Paula Schaap

As assistant managing editor, markets, Paula Schaap leads The Deal's coverage of activist investor campaigns and the equity and debt markets, as well as hedge fund and private equity news.

Prior to joining The Deal, Paula was editor of HedgeFund.net and a reporter in the New York office of London-based Financial News, now a division of Dow Jones.

Paula also worked as an editor for American Lawyer Media after leaving a business litigation practice in New York to become a journalist.

Recent Articles By The Author

NY Military Academy, Trump's Alma Mater, Is Readied for Auction

NY Military Academy, Trump's Alma Mater, Is Readied for Auction

New York Military Academy is asking the bankruptcy court to approve its hiring Hilco Real Estate to take care of an upcoming auction process and market the property.

Blockbuster Summer Movies Have High Impact on RealD Activism

Blockbuster Summer Movies Have High Impact on RealD Activism

Theater technology company RealD is having a blockbuster summer, along with rival Imax, as special effect movies like Jurassic World, Furious 7 and Avengers land in a theater near you.

To Win a Proxy Fight, Win the Heart of a Qualified Board Nominee

To Win a Proxy Fight, Win the Heart of a Qualified Board Nominee

As insurgencies proliferate, investors and targets are fishing in the same small pool of candidates. Experienced executives are the ideal recruits -- and companies may have an advantage over activists.

How Much CEO Pay Is Too Much? The Experts Weigh In

How Much CEO Pay Is Too Much? The Experts Weigh In

An investor, a lawyer, a banker and a consultant weigh in on the effect of shareholder anger over executive compensation.

Health Snacks Sector Pops as SkinnyPop Hires Adviser for Deal

Health Snacks Sector Pops as SkinnyPop Hires Adviser for Deal

With valuations high for healthy snack companies, SkinnyPop couldn't refuse to get back on the auction block.

Teva's $40B Bid for Mylan Comes in Wake of Perrigo Deal

Teva's $40B Bid for Mylan Comes in Wake of Perrigo Deal

As Israel's Teva Pharmaceutical Industries (TEVA) unveiled its $82 per share bid for Mylan (MYL) Tuesday, the hostile takeover attempt may be a harbinger of things to come.

Piercing the Once-Impregnable Steel Veil at Dual-Share Companies

Piercing the Once-Impregnable Steel Veil at Dual-Share Companies

Insurgents are finding ways to apply pressure, especially where the nature of the ownership is depressing stock prices.

March Mergers Take Off With Multi-Billion Tech, Healthcare Deals

March Mergers Take Off With Multi-Billion Tech, Healthcare Deals

March madness has nothing on Wall Street as the first Monday in the month kicks off with several multi-billion dollar deals.

10 Big Investors No Company CEO Ever Wants to Hear From

10 Big Investors No Company CEO Ever Wants to Hear From

Shareholder activists are mounting campaigns at a record pace, and few are more successful and feared than these ten.

Bluemercury Ready For Its Sale, After Opting Out of Public Debut

Bluemercury Ready For Its Sale, After Opting Out of Public Debut

Luxury brand retail chain and e-commerce provider Bluemercury has been put up for sale, The Deal's Sarah Pringle exclusively reports, after it decided not to go the IPO route.